Clinical Trials

For some patients, clinical trials offer a source of hope that a new treatment will provide the medical intervention they need to win their battle against cancer. These treatment trials also provide the critical research necessary to continue the search for a cure.

Cancer patients treated in well-organized clinical trials, in general, do as well or better than patients receiving "standard" treatments, particularly in difficult cancers where traditional treatments have not had a high success rate.

Experiencing tremendous growth since its establishment, the Penn State Hershey Cancer Institute at Mount Nittany Medical Center continues to participate in clinical research.

Contact Information

Please direct any questions to a Penn State Hershey Cancer Institute trials office staff member:

Breast

Adjuvent

 

408-C-1306:
A Randomized, Double-Blind, Vehicle-Controlled, Parallel-Group Phase 2 Study of Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of RTA 408 Lotion in the Treatment of Patients at Risk for Radiation Dermatitis 408-C-1306 Clinical Abstract (PDF)
NSABP B-43:
A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with Radiation Therapy and Radiation Therapy Alone for Women with HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy. NSABP B-43 Clinical Abstract (PDF)
NSABP B-47:
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel to Chemotherapy) plus Trastuzumab in Women with Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer. NSABP B-47 Clinical Abstract (PDF)
S1007:
A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER2 Negative Breast Cancer with Recurrence Score (RS) of 25 or less. S1007 Clinical Abstract (PDF)

Metastatic

E2108:
A Randomized Phase III Trial of the Value of Early Local Therapy for the Intact Primary Tumor in Patients with Metastatic Breast Cancer. E2108 Clinical Abstract (PDF)

Phyllodes Tumor

D0929:
A prospective Study of Partial Breast Adjuvant Radiation Therapy After Resection of Borderline and Malignant Phyllodes Tumors
 

GI

Metastatic

There are no trials at this time.

Adjuvant

CALGB 80702:
A Phase III Trial of 6 versus 12 Treatments of Adjusted Folfox plus Celecoxib or Placebo for Patients with Resected Stage III Colon Cancer. CALGB 80702 Clinical Abstract (PDF)

Thoracic

Adjuvant

S0819:
A Randomized, Phase III Study Comparing Carboplatin/Paclitaxel or Carbolpatin/Paclitaxel/Bevacizumab with or without Concurrent Cetuximab in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC). S0819 Clinical Abstract (PDF)
E5508:
A Randomized Phase III Study of Maintenance Therapy with Bevacizumab, Pemetrexed, or a Combination of Bevacizumab and Pemetrexed Following Carboplatin, Paclitaxel and Bevacizumab for Advanced Non-Squamous NSCLC. E5508 Clinical Abstract (PDF)

Leukemia

There are no trials at this time.

Lymphoma

E2408:
A 3-Arm Randomized Phase II Trial of Bendamustine-Rituximab (BR) Followed by Rituximab vs Bortezomib-BR (BVR) Followed by Rituximab vs BR Followed by Lenalidomide/Rituximab in High Risk Follicular Lymphoma. E2408 Clinical Abstract (PDF)
E1411:
Intergroup Randomized Phase II Four Arm Study In Patients With Previously Untreated Mantle Cell Lymphoma Of Therapy With: Arm A = Rituximab+ Bendamustine Followed By Rituximab Consolidation (RB → R); Arm B = Rituximab + Bendamustine + Bortezomib Followed By Rituximab Consolidation (RBV→ R), Arm C = Rituximab + Bendamustine Followed By Lenalidomide + Rituximab Consolidation (RB → LR) or Arm D = Rituximab + Bendamustine + Bortezomib Followed By Lenalidomide + Rituximab Consolidation (RBV → LR) )
E1411 Clinical Abstract (PDF)

Multiple Myeloma

There are no trials at this time.

Hematology

E2905:
A Randomized Phase III Trial Comparing the Frequency of major Erythroid Response (MER) to Treatment with Lenalidomide (revlimid) Alone and in Combination with Epoetin Alfa (Procrit) in Subjects with Low- or Intermediate-1 Risk MDS and Symptomatic Anemia. E2905 Clinical Abstract (PDF)

Head & Neck

There are no trials at this time.

Melanoma

There are no trials at this time.

Prevention

There are no trials at this time. 

GU

CTP-2:
Intensity Modulated Radiation Therapy followed by Cesium-131 Brachytherapy for Intermediate and High Risk Localized Prostate Cancer. CTP-2 Clinical Abstract

C70807:
The Men’s Eating and Living (MEAL) Study: A Randomized Trial of Diet to Alter Disease Progression in Prostate Cancer Patients on Active Surveillance. C70807 Clinical Abstract

GYN

RTOG 1203:
A Randomized Phase III Study of Standard vs IMRT Pelvic Radiation for Post-Operative Treatment of Endometrial and Cervical Cancer (TIME-C). RTOG 1203 Clinical Abstract

Barbara Gutch, RN, OCN
Clinical Research Coordinator
Phone: 814.231.7843
Fax: 814.231.7039
Email:bgutch@mountnittany.org

Shannon Fisher, RN
Clinical Research Coordinator
Phone: 814.231.7813
Fax: 814.231.7039
Email: sfisher@mountnittany.org

Amy Long, BS, CCRP
Data Manager
Phone: 814.231.7810
Fax: 814.231.7039
Email: along@mountnittany.org

The Foundation’s 21st Annual Golf Tournament raised $150,000 for the new Cancer Center.

More Info